ES2113670T3 - Vacunas contra virus respiratorio sincitial inactivadas. - Google Patents

Vacunas contra virus respiratorio sincitial inactivadas.

Info

Publication number
ES2113670T3
ES2113670T3 ES94923619T ES94923619T ES2113670T3 ES 2113670 T3 ES2113670 T3 ES 2113670T3 ES 94923619 T ES94923619 T ES 94923619T ES 94923619 T ES94923619 T ES 94923619T ES 2113670 T3 ES2113670 T3 ES 2113670T3
Authority
ES
Spain
Prior art keywords
virus
immunogenic composition
purified
inactivated
sincitial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923619T
Other languages
English (en)
Inventor
Sonia E Sanhueza
Mary Elizabeth Ewasyshyn
Michel Henri Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Connaught Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories Ltd filed Critical Connaught Laboratories Ltd
Application granted granted Critical
Publication of ES2113670T3 publication Critical patent/ES2113670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Abstract

SE PRESENTA UNA COMPOSICION INMUNOGENICA CAPAZ DE PRODUCIR UNA RESPUESTA INMUNE ESPECIFICA PARA EL VIRUS SINCIATIAL RESPIRATORIO (RS) EN UN ANFITRION INMUNIZADO CON LA MISMA, LA COMPOSICION COMPRENDE VIRUS RS PURIFICADO, INSACTIVADO QUE ESTA SUBSTANCIALMENTE LIBRE DE COMPONENTES CELULARES Y DEL SUERO Y QUE NO ES INFECCIOSO, NO ES INMUNOPOTENCIADOR, ES INMUNOGENICO Y ES PROTECTOR. EL VIRUS SE HACE CRECER EN UNA LINEA CELULAR DE CALIDAD DE VACUNA Y EL VIRUS COSECHADO SE PURIFICA BAJO CONDICIONES NO DESNATURALIZADORAS PARA QUE ESTE SUBSTANCIALMENTE LIBRE DE COMPONENTES CELULARES Y DEL SUERO. EL VIRUS RS PURIFICADO SE INACTIVA UTILIZANDO {BE}-PROPIOLACTONA, UN DETERGENTE NO IONICO, PARTICULARMENTE N-OCTIL-{AL}-DGLUCOPYRANOSIDO Y N-OCTIL-{BE}-D-GLUOCOPIRANOSIDO, O ACIDO ASCORBICO, LA COMPOSICION INMUNOGENICA PUEDE FORMULARSE COMO VACUNA PARA LA ADMINISTRACION "IN VIVO" A UN ANFITRION HUMANO. LA COMPOSICION INMUNOGENICA TAMBIEN PUEDE UTILIZARSE EN APLICACIONES DE DIAGNOSTICO.
ES94923619T 1993-08-06 1994-08-04 Vacunas contra virus respiratorio sincitial inactivadas. Expired - Lifetime ES2113670T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10274293A 1993-08-06 1993-08-06

Publications (1)

Publication Number Publication Date
ES2113670T3 true ES2113670T3 (es) 1998-05-01

Family

ID=22291469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923619T Expired - Lifetime ES2113670T3 (es) 1993-08-06 1994-08-04 Vacunas contra virus respiratorio sincitial inactivadas.

Country Status (15)

Country Link
US (1) US7083795B1 (es)
EP (1) EP0714306B1 (es)
JP (1) JP4053587B2 (es)
KR (1) KR100402379B1 (es)
CN (1) CN1103603C (es)
AT (1) ATE164313T1 (es)
AU (1) AU677090B2 (es)
BR (1) BR9407182A (es)
CA (1) CA2167274C (es)
DE (1) DE69409243T2 (es)
DK (1) DK0714306T3 (es)
ES (1) ES2113670T3 (es)
GR (1) GR3026619T3 (es)
RU (1) RU2142817C1 (es)
WO (1) WO1995004545A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243491A1 (de) * 1992-12-22 1994-06-23 Behringwerke Ag Verfahren zur Reinigung und Anreicherung von Rubella-Virus
EP2590675B1 (en) * 2010-07-07 2018-08-29 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
CA3157421A1 (en) * 2019-12-10 2021-06-17 Amit Kumar Dutta Methods of preparing viral vectors
EP4281065A1 (en) 2021-01-20 2023-11-29 Alto Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043272B1 (en) * 1980-07-01 1984-06-13 National Research Development Corporation Production of viral antigens
US4591505A (en) * 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4664912A (en) 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5200179A (en) * 1987-09-28 1993-04-06 Beecham Group P.L.C. Vaccine
IE66015B1 (en) 1987-09-28 1995-11-29 Beecham Inc TGEV-virus of swine as a dog vaccine
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
DK0714306T3 (da) 1998-10-19
BR9407182A (pt) 1996-09-17
CA2167274C (en) 2007-11-27
JPH09501912A (ja) 1997-02-25
DE69409243T2 (de) 1998-08-06
CN1133013A (zh) 1996-10-09
ATE164313T1 (de) 1998-04-15
JP4053587B2 (ja) 2008-02-27
EP0714306A1 (en) 1996-06-05
KR960703618A (ko) 1996-08-31
WO1995004545A1 (en) 1995-02-16
DE69409243D1 (de) 1998-04-30
RU2142817C1 (ru) 1999-12-20
CN1103603C (zh) 2003-03-26
EP0714306B1 (en) 1998-03-25
AU7380194A (en) 1995-02-28
US7083795B1 (en) 2006-08-01
KR100402379B1 (ko) 2004-03-24
CA2167274A1 (en) 1995-02-16
GR3026619T3 (en) 1998-07-31
AU677090B2 (en) 1997-04-10

Similar Documents

Publication Publication Date Title
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
GR3019112T3 (en) Porcine reproductive respiratory syndrome vaccine and diagnostic.
BR9510263A (pt) Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
HU229368B1 (en) Novel vaccine composition
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
ES2074950A1 (es) Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
HUP0401606A2 (hu) West Nile vakcina
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
EP0480949B1 (en) Production of virus and purification of viral envelope proteins for vaccine use
MXPA01006214A (es) Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
ES379641A1 (es) Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos.
ES2113670T3 (es) Vacunas contra virus respiratorio sincitial inactivadas.
ATE354370T1 (de) Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen
ATE220067T1 (de) 4-(2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl)- - cyclopenten-1-methanol-succinat als antivirales mittel
Stittelaar et al. Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
AU5573196A (en) A pluripotent vaccine against enveloped viruses
DK56389A (da) Forhindring og behandling af retroviralt frembragte sygdomme
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
Lestari et al. Prospect of dengue vaccine development with halal process-based technology
NL300073I1 (nl) Vaccin.
RU2099086C1 (ru) Способ профилактики гриппа у детей живой гриппозной вакциной

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 714306

Country of ref document: ES